EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TFAB002s, novel CD20-targeting T cell-dependent bispecific Fab-FabCH3 antibodies, exhibit potent antitumor efficacy against malignant B-cell lymphoma

Qinghong Li iD, Kunming Zhang, Yao Yu, Zeng Yu, Jingyi Xu, Wenyan Shen, Lin Zhang, Aidong Qu, Hongyuan Liang iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0310889 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Qinghong Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: No.1 Research Laboratory, Shanghai Institute of Biological Products Co., Ltd., Shanghai, China. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antigens, CD20, Lymphoma, B-Cell, Immunoglobulin Fab Fragments. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

B-cell lymphoma, clinically, comprises a heterogeneous group of malignancies that encompass various subtypes. CD20 is an optimal target for therapeutic antibodies in B-cell lymphoma immunotherapy since approximately 90% of B-cell malignancies typically exhibit CD20 expression on their surface, while its presence is limited in normal tissues. In this study, we have developed a series of novel non-IgG-like T cell-dependent bispecific antibodies by constructing Fab-FabCH3, referred to as Tandem Antigen-binding Fragment 002 (TFAB002), which specifically target CD20 for the treatment of malignant B-cell lymphoma. TFAB002s display strong binding affinity with CD20 and moderate binding affinity with CD3, thereby triggering target-specific T-cell activation, cytokine release, and tumor cell lysis in vitro . Furthermore, TFAB002s exhibit potent cytotoxicity against B-cell malignancies that express varying levels of CD20. Besides, the TFAB002s show potent pharmacodynamic activity in vivo in the WIL2-S cells CDX mouse model. Collectively, these results underscore the potential of TFAB002s as a highly promising therapeutic approach for selectively depleting CD20-positive B cells, thereby warranting further clinical evaluation as a viable treatment option for CD20-expressing B-cell malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificAntigens, CD20Lymphoma, B-CellImmunoglobulin Fab FragmentsT-LymphocytesAnimalsMiceHumansCell Line, TumorXenograft Model Antitumor AssaysLymphocyte ActivationFemale

Substanzen

Antibodies, BispecificAntigens, CD20Immunoglobulin Fab Fragments

Autor:innen und Institutionen

  • No.1 Research Laboratory, Shanghai Institute of Biological Products Co., Ltd., Shanghai, China.

ORCID-Profile: Qinghong Li, Hongyuan Liang

Zitieren

APA

Li, Q., Zhang, K., Yu, Y., Yu, Z., Xu, J., Shen, W., Zhang, L., Qu, A., & Liang, H. (2024). TFAB002s, novel CD20-targeting T cell-dependent bispecific Fab-FabCH3 antibodies, exhibit potent antitumor efficacy against malignant B-cell lymphoma. PLOS ONE. https://doi.org/10.1371/journal.pone.0310889

Vancouver

Li Q, Zhang K, Yu Y, Yu Z, Xu J, Shen W, et al. TFAB002s, novel CD20-targeting T cell-dependent bispecific Fab-FabCH3 antibodies, exhibit potent antitumor efficacy against malignant B-cell lymphoma. PLOS ONE. 2024. doi:10.1371/journal.pone.0310889

BibTeX
@article{Li2024,
  author = {Li, Qinghong and Zhang, Kunming and Yu, Yao and Yu, Zeng and Xu, Jingyi and Shen, Wenyan and Zhang, Lin and Qu, Aidong and Liang, Hongyuan},
  title = {TFAB002s, novel CD20-targeting T cell-dependent bispecific Fab-FabCH3 antibodies, exhibit potent antitumor efficacy against malignant B-cell lymphoma},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0310889}
}
Kostenlos starten →